PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer - United States
doi 10.1016/j.currproblcancer.2010.12.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PARP Inhibitors in Ovarian Cancer

2013English

An Effective Epigenetic-Parp Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations

Clinical Cancer Research
Cancer ResearchOncology
2018English

The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2015English

PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2017English

MA22.01 PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Treatment of Breast Cancer 2 (BRCA2)-mutant Follicular Dendritic Cell Sarcoma With a Poly ADP-ribose Polymerase (PARP) Inhibitor: A Case Report

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy